Pyxis Oncology logo
Pyxis Oncology
PYXS | NASDAQ
Chart Builder DCF Calculator
$1.41
-$0.17 (-10.76%)
At close: Nov 16, 2026, 4:00 PM ET
$1.43
+$0.02 (+1.29%)
After-hours: Nov 16, 2026, 7:06 PM ET

Pyxis Oncology Company Profile

Company profile explained

Company Profile

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.

Key Executives

Name Position
Thomas Civik CEO & Chairman
Balu N. Balasubramanian Interim Chief Technology Officer
Charles T. Gombar Senior Vice President of Portfolio & Program Management
Donna Regalado Head of Human Resources
Hongwei Wang Head of ADC Development & Clinical Strategy
Jitendra Wadhane Chief Accounting Officer, Senior Vice President of Finance, Corporate Controller & Principal Financial Officer
Marsha Crochiere Head of Translational Medicine & Research
Michael Bui Senior Vice President of Global Regulatory Affairs
Shui He Head of Biometrics
Stan Szpindor Head of R&D Quality
Supriya Roth Head of Commercial Development

Latest SEC Filings

Date Type Title
Oct 21, 2026 DEF 14A Filing
Oct 09, 2026 PRE 14A Filing
Oct 09, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 09, 2026 4/A [Amend] Filing
Oct 05, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 02, 2026 4 Filing
Oct 02, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 01, 2026 8-K Current Report
Oct 01, 2026 424B5 Filing
Sep 29, 2026 424B5 Filing
View All SEC Filings ➞
Pyxis Oncology
Pyxis Oncology logo
Country United States
IPO Date Oct 8, 2021
Industry Biotechnology
Sector Healthcare
Employees 56
CEO Thomas Civik

Contact Details

321 Harrison Avenue Boston, Massachusetts 02118 United States

Stock Details

Ticker Symbol PYXS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001782223
CUSIP Number 747324101
ISIN Number US7473241013
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.